Tandem Diabetes’s (NASDAQ:TNDM) Q4 Sales Beat Estimates But Stock Drops 12.2%
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 35% year on year to $282.6 million. The company expects next quarter’s revenue to be around $221.5 million, coming in 1.3% above analysts’ estimates. Its GAAP profit of $0.01 per share was significantly above analysts’ consensus estimates.